US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,839.06

+18.751.03%

Number of Gainers:11

Number of Losers:7

Number of Flat:- -

PE:- -

High:1,844.35

Open:1,819.74

Low:1,815.03

Close:1,820.31

Volume:98.02M

Turnover:6.47B

Market Cap:1.50T

Float Cap:1.48T

Loading ...

Sciwind Biosciences and Pfizer China Forge Strategic Partnership for Ecnoglutide Commercialization

EQ Resources Completes Documents for Prepayment Facility Repayable via Set-Off Against Monthly Tungsten Oxide Concentrate Deliveries, Shares Fall 3%

MT Newswires Live

COLUMN-Novartis quietly settles Henrietta Lacks suit as family’s legal push gains steam

Hangzhou Sciwind Biosciences and Pfizer China Announce Strategic Cooperation Agreement on Commercialisation of New Generation of Ecnoglutide Injection

THOMSON REUTERS

EQ Resources Refinances Spanish Debt With €15m Traxys Prepayment Deal

Vir Biotechnology Inc reports results for the quarter ended September 30 - Earnings Summary

Law firm Gibson Dunn loses appeal over ex-partner's retirement pay

Vir Biotechnology Q4 Loss Narrows, Revenue Rises

MT Newswires Live

Vir Biotechnology Q4 revenue beats estimates

Johnson & Johnson EVP, WW Chair, MedTech Timothy Schmid Disposes of Common Shares

BRIEF-Vir Biotechnology Q4 EPS USD -0.31

Vir posts Q4 revenue of USD 64.1 million up 5.17x

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS

Vir Biotechnology reports new VIR-5500 data

Astellas, Vir announce global strategic collaboration

Vir Biotechnology reports positive updated Phase 1 results for PSMA-targeting T-cell engager VIR-5500 in metastatic prostate cancer

Vir Biotechnology Inc: Advancing Dose-Expansion Cohorts and Plan to Initiate Our Registrational Trial in 2027

THOMSON REUTERS

Vir Biotechnology Inc - Vir-5500 Shows Favorable Safety Profile With No Dose-Limiting Toxicities

THOMSON REUTERS

Vir Biotechnology: 82% Psa50 & 53% Psa90 Declines & Recist-Evaluable Objective Responses in ≥3,000 ΜG/Kg Q3w Dosing Cohorts With Vir-5500

THOMSON REUTERS

Vir Biotechnology Reports Positive Updated Phase 1 Results for Psma-Targeting, Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 in Patients With Metastatic Prostate Cancer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1839.0577,"timestamp":1771880399999,"preClose":1820.3057,"halted":0,"volume":98023433,"delay":0,"changeRate":0.010302,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":18.752075,"latestTime":"02-23 16:00:00 EST","open":1819.7351,"high":1844.3469,"low":1815.031,"amount":6470786377.296041,"amplitude":0.016105,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771923600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.576431,"peRate":26.855529,"turnoverRate":0.007083,"increases":11,"decrements":7,"flats":0,"marketCap":1503745191758.25,"floatMarketCap":1479908328347.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1844.3469,"amplitude":0.016105,"preClose":1820.3057,"low":1815.031,"pbRate":"4.576431","latestPrice":1839.0577,"volume":98023433,"delay":0,"open":1819.7351,"prevYearClose":1637.1339,"prevWeekClose":1820.3057,"prevMonthClose":1721.4615,"prevQuarterClose":1637.1339,"fiveDayClose":1833.2484,"twentyDayClose":1685.1011,"sixtyDayClose":1637.046,"secType":"PLATE","market":"US","turnoverRate":0.007083,"peRate":26.855529,"marketCap":1503745191758.25,"floatMarketCap":1479908328347.25,"timestamp":1771880399999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":11,"down":7,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1149060519","title":"Sciwind Biosciences and Pfizer China Forge Strategic Partnership for Ecnoglutide Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=1149060519","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149060519?lang=en_us&edition=fundamental","pubTime":"2026-02-24 10:34","pubTimestamp":1771900489,"startTime":"0","endTime":"0","summary":"Hangzhou Sciwind Biosciences Co., Ltd. and Pfizer China announced today that they have entered into a strategic commercialization agreement for the next-generation biased GLP-1 receptor agonist,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","BK4007","SG9999013999.USD","SG9999001176.USD","LU0058720904.USD","LU0170899867.USD","IE00BLSP4239.USD","IE0002270589.USD","LU0225284248.USD","BK4599","IE00B19Z3B42.SGD","IE00B19Z3581.USD","91078","BK4588","LU0868494617.USD","LU1023059063.AUD","LU1057294990.SGD","BK4592","LU0289739699.SGD","LU1894683264.USD","LU1894683348.USD","LU0306807586.USD","IE000M9KFDE8.USD","PFE","LU0225771236.USD","BK4568","BK4581","IE00BBT3K403.USD","LU0122379950.USD","BK4533","SG9999001176.SGD","LU0985481810.HKD","LU0321505439.SGD","SG9999002224.SGD","SG9999002232.USD","IE00BLSP4452.SGD","SGXZ57979304.SGD","SG9999011175.SGD","BK4550","LU0321505868.SGD","LU0306806265.USD","LU1066053197.SGD","BK4534","SG9999003800.SGD","LU0234572021.USD","BK4585","LU1883839398.USD","LU1066051498.USD"],"gpt_icon":1},{"id":"2613757910","title":"EQ Resources Completes Documents for Prepayment Facility Repayable via Set-Off Against Monthly Tungsten Oxide Concentrate Deliveries, Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613757910","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613757910?lang=en_us&edition=fundamental","pubTime":"2026-02-24 10:10","pubTimestamp":1771899013,"startTime":"0","endTime":"0","summary":"EQ Resources  completed its transaction documents with Traxys Europe for a three-year 15 million euros prepayment facility repayable via set-off against monthly concentrate deliveries of tungsten oxide, while also entering into a five-year commercial agreement with Traxys, under which 3,500 tonnes of tungsten oxide produced from its Barruecopardo mine in Spain will be sold to Traxys at the prevailing spot price of delivery, according to a Tuesday Australian bourse filing.The value of the commercial agreement is around AU$678 million, based on current spot prices.The proceeds from the prepayment facility will be used to refinance 15 million euros of the existing debt facilities owed by the firm's wholly-owned subsidiary Salaro.Its shares fell 3% in recent trading on Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","EQR.AU","BK4139","EQ","BK4568"],"gpt_icon":0},{"id":"2613383752","title":"COLUMN-Novartis quietly settles Henrietta Lacks suit as family’s legal push gains steam","url":"https://stock-news.laohu8.com/highlight/detail?id=2613383752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613383752?lang=en_us&edition=fundamental","pubTime":"2026-02-24 09:32","pubTimestamp":1771896727,"startTime":"0","endTime":"0","summary":"COLUMN-Novartis quietly settles Henrietta Lacks suit as family’s legal push gains steamThe opinions expressed here are those of the author, a columnist for Reuters.By Jenna Greene","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL1N3ZJ0ZI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","LU1989771016.USD","LU2468319806.SGD","BK4139","BK4581","IE00B1BXHZ80.USD","IE0034235188.USD","LU0528227936.USD","LU1983299246.USD","LU1854104046.USD","LU0225284248.USD","IE00B19Z3581.USD","LU1291159041.SGD","LU1670628061.USD","LU2112291526.USD","BK4007","LU1923622614.USD","LU0306806265.USD","LU0640476718.USD","LU2720916845.USD","BK4533","LU2041044095.USD","LU2211814178.USD","LU2125909916.SGD","BK4568","LU2092937221.SGD","LU0957791311.USD","LU1923622291.USD","IE0002141913.USD","LU1720051108.HKD","LU1066051498.USD","LU1803068623.USD","LU0266013472.USD","LU0321505439.SGD","LU1883839398.USD","LU0342679015.USD","LU2087621335.USD","LU1670627923.USD","LU0320765489.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","LU1280957306.USD","LU0170899867.USD","IE00B19Z8X17.USD","LU2433249047.HKD","LU2298321311.HKD","LU1894683264.USD","BK4592","LU0345770308.USD","SG9999011175.SGD","BK4121","LU1066053197.SGD","LU0225771236.USD","LU0070302665.USD","LU2125910336.SGD","BK4548","LU1923621640.USD","LU0289739699.SGD","LU2125909247.SGD","LU1791710400.SGD","LU0234572021.USD","SG9999003800.SGD","LU0011850046.USD","LU2764263203.CNY","BK4535","SG9999001176.USD","IE00BJJMRZ35.SGD","LU1988902786.USD","IE00BLSP4239.USD","SG9999002232.USD","IE00B2B36J28.USD","BK4585","LU2764262908.HKD","LU0985481810.HKD","LU1548497426.USD","LU0557290698.USD","BK4599","LU2360108059.USD","LU2125909593.SGD","LU1839511570.USD","LU2089984988.USD","LU1854103824.USD","BK4534","IE00BJT1NW94.SGD","LU1023059063.AUD","LU0345770993.USD","LU1633808545.USD","LU0316494557.USD","LU0114720955.EUR","LU0061474960.USD","LU0306807586.USD","LU1061106388.HKD","LU0882574055.USD","LU2764263039.SGD","BK4588","IE000M9KFDE8.USD","IE00B19Z8W00.USD","LU0868494617.USD","LU2125910179.SGD","IE00BKPKM429.USD","IE00BLSP4452.SGD","LU0208291251.USD","GB00BDT5M118.USD","LU1064131342.USD","LU0122379950.USD","SG9999002224.SGD","LU0823416689.USD","LU1720051017.SGD","LU1623119135.USD","SGXZ57979304.SGD","SG9999001176.SGD","LU1894683348.USD","IE00BBT3K403.USD","LU1712237335.SGD","IE00B19Z9505.USD","LU0096362180.USD","BK4566","NVS","IE0009355771.USD","LU0058720904.USD","IE00B4R5TH58.HKD","LU0456855351.SGD","LU1815333072.USD","LU1057294990.SGD","LU2063271972.USD","LU2357305700.SGD","LU2264538146.SGD","LU2125909759.SGD","BK4550","LU1791710582.SGD","SG9999013999.USD","BK4583","LU1153585028.USD","LU0321505868.SGD","IE00BFTCPJ56.SGD","LU2211815571.USD"],"gpt_icon":0},{"id":"2613754721","title":"Hangzhou Sciwind Biosciences and Pfizer China Announce Strategic Cooperation Agreement on Commercialisation of New Generation of Ecnoglutide Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2613754721","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613754721?lang=en_us&edition=fundamental","pubTime":"2026-02-24 09:28","pubTimestamp":1771896511,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nP8N3Y004S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1894683264.USD","LU0122379950.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU0868494617.USD","BK4585","BK4568","LU0456855351.SGD","BK4550","IE00BLSP4239.USD","SG9999002224.SGD","BK4592","LU1883839398.USD","LU1023059063.AUD","LU1066051498.USD","LU1894683348.USD","BK4534","LU0321505439.SGD","IE00BLSP4452.SGD","02252","LU0985481810.HKD","LU0289739699.SGD","BK4533","LU0321505868.SGD","LU0234572021.USD","SG9999001176.USD","SG9999001176.SGD","LU0058720904.USD","BK4007","BK4581","LU0170899867.USD","LU1057294990.SGD","SG9999002232.USD","LU0306806265.USD","IE0002270589.USD","PFE","BK4599","SG9999013999.USD","BK4588","IE00BBT3K403.USD","LU1066053197.SGD","LU0225771236.USD","SG9999011175.SGD","LU0306807586.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","SG9999003800.SGD","LU0225284248.USD"],"gpt_icon":0},{"id":"2613596797","title":"EQ Resources Refinances Spanish Debt With €15m Traxys Prepayment Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2613596797","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613596797?lang=en_us&edition=fundamental","pubTime":"2026-02-24 08:08","pubTimestamp":1771891703,"startTime":"0","endTime":"0","summary":"EQ Resources Limited ( ($AU:EQR) ) has issued an announcement. EQ Resources has arranged a three-year €15 million prepayment facility with commodit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eq-resources-refinances-spanish-debt-with-e15m-traxys-prepayment-deal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eq-resources-refinances-spanish-debt-with-e15m-traxys-prepayment-deal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EQ","BK4568"],"gpt_icon":0},{"id":"2613565227","title":"Vir Biotechnology Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2613565227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613565227?lang=en_us&edition=fundamental","pubTime":"2026-02-24 07:44","pubTimestamp":1771890246,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc reports results for the quarter ended September 30 - Earnings SummaryVir Biotechnology Inc VIR.OQ reported a quarterly adjusted loss of 31 cents per share for the quarter ended S","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL8N3ZJ2KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4585","BK4535","VIR","BK4139"],"gpt_icon":0},{"id":"2613980755","title":"Law firm Gibson Dunn loses appeal over ex-partner's retirement pay","url":"https://stock-news.laohu8.com/highlight/detail?id=2613980755","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613980755?lang=en_us&edition=fundamental","pubTime":"2026-02-24 07:08","pubTimestamp":1771888134,"startTime":"0","endTime":"0","summary":"Law firm Gibson Dunn loses appeal over ex-partner's retirement payBy Mike Scarcella. Gibson Dunn loses ruling in pay fight with $60 million ex-partner","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL6N3ZJ10O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU0648001328.SGD","LU0985481810.HKD","LU1059921491.USD","LU1244550221.USD","LU0289739699.SGD","LU0225284248.USD","IE00B894F039.SGD","BK4115","LU1150488135.SGD","LU0321505868.SGD","LU1066053197.SGD","SG9999013999.USD","LU1023059063.AUD","LU0708994859.HKD","IE000M9KFDE8.USD","SG9999011175.SGD","LU0225771236.USD","LU0985489474.SGD","LU1267930573.SGD","BK4100","LU0321505439.SGD","IE00B19Z9Z06.USD","LU0058720904.USD","LU0068578508.USD","LU1074936037.SGD","BK4550","LU0310800379.SGD","IE00BBT3K403.USD","LU0122379950.USD","LU0980610538.SGD","BK4534","LU0029864427.USD","BK4533","LU1150488218.USD","LU0070302665.USD","LU1057294990.SGD","LU1244550494.USD","BK4007","IE00BSNM7G36.USD","LU1894683348.USD","SG9999002232.USD","BK4566","IE00BLSP4452.SGD","LU0433182093.SGD","SG9999001176.SGD","LU1883839398.USD","BK4599","IE00B19Z3B42.SGD","BK4598","SG9999002224.SGD","BK4588","LU0456855351.SGD","LU0878866978.SGD","LU1894683264.USD","LU0320765489.SGD","LU0942090050.USD","IE00BLSP4239.USD","BK4568","BK4507","LU0208291251.USD","CMCSA","LU0868494708.USD","SGXZ57979304.SGD","LU0234572021.USD","IE00B19Z3581.USD","LU1244550577.SGD","IE0002270589.USD","LU0306806265.USD","LU0868494617.USD","SG9999001176.USD","BK4585","SG9999003800.SGD","LU0306807586.USD","IE00B19Z9P08.USD","LU1066051498.USD","LU0170899867.USD","BK4592","LU0130102774.USD","LU0128525929.USD","LU1489326972.SGD","LU1201861249.SGD"],"gpt_icon":1},{"id":"2613153753","title":"Vir Biotechnology Q4 Loss Narrows, Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2613153753","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613153753?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:31","pubTimestamp":1771885866,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (VIR) reported a Q4 net loss late Monday of $0.31 per diluted share, narrowing from a loss of $0.76 a year earlier.Revenue for the quarter ended Dec. 31 was $64.1 million, up from $12.4 million a year earlier.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4568","BK4535","BK4585","BK4139","VIR"],"gpt_icon":0},{"id":"2613753694","title":"Vir Biotechnology Q4 revenue beats estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2613753694","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613753694?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:23","pubTimestamp":1771885387,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Q4 revenue beats estimatesOverviewBiopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenueCompany reported a net loss for Q4, decreased compar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL1N3ZJ159:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","VIR","BK4585","BK4568","BK4139"],"gpt_icon":0},{"id":"2613656753","title":"Johnson & Johnson EVP, WW Chair, MedTech Timothy Schmid Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2613656753","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613656753?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:21","pubTimestamp":1771885262,"startTime":"0","endTime":"0","summary":"Timothy Schmid, EVP, WW Chair, MedTech at Johnson and Johnson, reported a disposal of common shares of Johnson and Johnson. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL3vWz8w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Johnson & Johnson EVP, WW Chair, MedTech Timothy Schmid Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1506573853.SGD","BK4559","BK4533","LU0203345920.USD","LU1674673691.USD","BK4504","IE00B2B36J28.USD","BK4550","LU1244550577.SGD","LU1066053197.SGD","LU2430703095.HKD","IE00B1BXHZ80.USD","LU2471134952.CNY","LU1032466523.USD","IE00BLSP4239.USD","LU0345770993.USD","LU1023059063.AUD","BK4534","LU1221951046.USD","IE00B42XCP33.USD","LU1074936037.SGD","LU1244550221.USD","LU1935042991.SGD","LU1732799900.SGD","IE00BBT3K403.USD","IE00BSNM7G36.USD","LU1244550494.USD","JNJ","BK4007","LU2505996681.GBP","LU2471134879.HKD","LU0795875169.SGD","LU1196500208.SGD","LU0234572021.USD","LU1066051498.USD","BK4592","BK4568","LU0640476718.USD","LU2505996509.AUD","IE00BDGV0183.EUR","IE00BGHQF631.EUR","LU1066051811.HKD","IE00BFXG1179.USD","LU2602419157.SGD","LU2129689514.USD","LU0683600562.USD","LU1674673428.USD","IE00B19Z3B42.SGD","LU2129689431.USD","IE0002270589.USD"],"gpt_icon":0},{"id":"2613753820","title":"BRIEF-Vir Biotechnology Q4 EPS USD -0.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2613753820","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613753820?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:14","pubTimestamp":1771884885,"startTime":"0","endTime":"0","summary":"BRIEF-Vir Biotechnology Q4 EPS USD -0.31\n\n\nFeb 23 (Reuters) - Vir Biotechnology Q4 revenue USD 64.1 million vs. IBES estimate USD 23.2 million.\n\nQ4 net income USD -42.9 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nPLX41D8E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","VIR","BK4568","BK4535"],"gpt_icon":0},{"id":"2613753870","title":"Vir posts Q4 revenue of USD 64.1 million up 5.17x","url":"https://stock-news.laohu8.com/highlight/detail?id=2613753870","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613753870?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:14","pubTimestamp":1771884875,"startTime":"0","endTime":"0","summary":"Vir posts Q4 revenue of USD 64.1 million up 5.17x               Vir reported Q4 2025 revenue of USD 64.1 million and a net loss attributable to shareholders of USD 42.9 million (USD 0.31 per share). R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDLc9tGhz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","VIR","BK4568","BK4535"],"gpt_icon":0},{"id":"2613758076","title":"Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2613758076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613758076?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:14","pubTimestamp":1771884840,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nTUA35VRNJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4535","BK4568","VIR","BK4139"],"gpt_icon":0},{"id":"2613753669","title":"Vir Biotechnology reports new VIR-5500 data","url":"https://stock-news.laohu8.com/highlight/detail?id=2613753669","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613753669?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:10","pubTimestamp":1771884634,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (VIR) announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen-targeting, Pro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-reports-new-vir-5500-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-reports-new-vir-5500-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","VIR","BK4568","BK4139","BK4535"],"gpt_icon":0},{"id":"2613535757","title":"Astellas, Vir announce global strategic collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2613535757","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613535757?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:05","pubTimestamp":1771884313,"startTime":"0","endTime":"0","summary":"Astellas Pharma (ALPMY) and Vir Biotechnology (VIR) announced they have entered into a global strategic collaboration to advance VIR-5500, an inves...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astellas-vir-announce-global-strategic-collaboration-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astellas-vir-announce-global-strategic-collaboration-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALPMY","BK4535","VIR","BK4139","BK4585","BK4568"],"gpt_icon":0},{"id":"2613075842","title":"Vir Biotechnology reports positive updated Phase 1 results for PSMA-targeting T-cell engager VIR-5500 in metastatic prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2613075842","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613075842?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:02","pubTimestamp":1771884134,"startTime":"0","endTime":"0","summary":"Vir Biotechnology reports positive updated Phase 1 results for PSMA-targeting T-cell engager VIR-5500 in metastatic prostate cancer. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL9ClXMD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","VIR","BK4585","BK4568","BK4139"],"gpt_icon":0},{"id":"2613758423","title":"Vir Biotechnology Inc: Advancing Dose-Expansion Cohorts and Plan to Initiate Our Registrational Trial in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2613758423","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613758423?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:02","pubTimestamp":1771884120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nTUA9WHGZF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","VIR","BK4585","BK4139","BK4568"],"gpt_icon":0},{"id":"2613675842","title":"Vir Biotechnology Inc - Vir-5500 Shows Favorable Safety Profile With No Dose-Limiting Toxicities","url":"https://stock-news.laohu8.com/highlight/detail?id=2613675842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613675842?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:02","pubTimestamp":1771884120,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nTUA9WHGZF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","VIR","BK4585","BK4535"],"gpt_icon":0},{"id":"2613582137","title":"Vir Biotechnology: 82% Psa50 & 53% Psa90 Declines & Recist-Evaluable Objective Responses in ≥3,000 ΜG/Kg Q3w Dosing Cohorts With Vir-5500","url":"https://stock-news.laohu8.com/highlight/detail?id=2613582137","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613582137?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:02","pubTimestamp":1771884120,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nTUA9WHGZF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","BK4585","VIR","BK4535"],"gpt_icon":0},{"id":"2613425758","title":"Vir Biotechnology Reports Positive Updated Phase 1 Results for Psma-Targeting, Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 in Patients With Metastatic Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2613425758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613425758?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:02","pubTimestamp":1771884120,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nTUA9WHGZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4568","BK4535","VIR"],"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":1,"totalSize":403,"code":"91000000","status":"200"}]}}